ETHE1-p.Arg163Gln and p.Arg163Trp are folded but have decreased stability. by Bárbara J. Henriques (627180)

ML246 and voluntary exercise decrease cerebral amyloid plaques and ameliorate memory deficits in 5XFAD AD mice. by Altea Rocchi (3278457)

Genetic correlations in viral load between single and coinfections of CrPV and DCV. by Ryan M. Imrie (15810854)

Subjects:

Interspecific correlations in viral load between single and coinfections of CrPV and DCV. by Ryan M. Imrie (15810854)

Subjects:

Relative fold change (relative to untreated control cells) of the EGFR gene among LS174T and IEC-18 cells. by Asadollahi Parisa (8837432)

Subjects:

DPOAE responses are decreased one week after treatment with 8,000 mg/kg HPβCD. by Mark A. Crumling (107429)

Effect of H5 (20 mg/kg, p.o.) on paw edema induced by histamine in mice. by Maria Alice Miranda Bezerra Medeiros (11752002)

JBPOS0101 decreased Amyloid Beta (Aβ) aggregates in the cortex and hippocampal regions in 5xFAD mouse brains. by Jihoon Jeong (4852690)

Effect of H5 (20 and 40 mg/kg, p.o.) and indomethacin (20 mg/kg, i.p.) on paw edema induced by carrageenan in mice. by Maria Alice Miranda Bezerra Medeiros (11752002)

Adverse events in low-dose naltrexone arm. by Judith I. Tsui (5983160)

Subjects:

CONSORT flow diagram. by Judith I. Tsui (5983160)

Subjects:

Adverse events in placebo arm. by Judith I. Tsui (5983160)

Subjects:

Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

Subjects:

Adverse events in gabapentin arm. by Judith I. Tsui (5983160)

Subjects:

Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

Subjects:

Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Subjects:

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Subjects:

Reishi decreases the expression of PI3K/AKT signaling pathway genes and of mTORC1 effectors. by Ivette J. Suarez-Arroyo (383847)

Fig 5 - by Kenichi Kiyomoto (12709675)

Subjects:

Mean and standard deviation of 5-point experience sampling scales for each group (treatment and control) and session (pre and post). by Julio Rodriguez-Larios (18778803)